Bilateral Gene Therapy Safely Restores Hearing in Children Born Deaf
By Elana Gotkine HealthDay Reporter
WEDNESDAY, June 5, 2024 -- For pediatric patients with autosomal recessive deafness 9 (DFNB9), bilateral gene therapy with adeno-associated virus (AAV) serotype 1 carrying human OTOF transgene is safe and efficacious, according to a study published online June 5 in Nature Medicine.
Hui Wang, M.D., from the Eye & ENT Hospital of Fudan University in Shanghai, and colleagues report on the results of an interim analysis of a single-arm trial examining the safety and efficacy of binaural therapy among five pediatric patients with DFNB9.
The researchers observed no dose-limiting toxicity at six weeks, nor any serious adverse events. Thirty-six adverse events occurred, with increased lymphocyte counts (six of 36) and increased cholesterol levels (six of 36) being the most common events. Bilateral hearing restoration occurred in all patients. The average auditory brainstem response threshold in the right (left) ear was restored to 58 (58) dB, 75 (85) dB, and 55 (50) dB in patients 1, 2, and 3, respectively, at 26 weeks and to 75 (78) dB and 63 (63) dB in patients 4 and 5, respectively, at 13 weeks compared with >95 (>95) dB in all patients at baseline. In all five patients, speech perception and capability of sound source localization were restored.
"Binaural AAV1-hOTOF gene therapy resulted in bilateral hearing restoration, the improvement of auditory and speech function, and the restoration of the ability of sound source localization in all treated patients," the authors write.
One author is employed by Shanghai Refresh Therapeutics Co., which funded the study; a second author is cofounder of Salubritas Therapeutics.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted June 2024
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.